NCT03594422 2026-04-09
A Study of HQP1351 in Patients With GIST or Other Solid Tumors
Ascentage Pharma Group Inc.
Phase 1 Recruiting
Clinical Trials
9 trialsNCT04501120 2025-09-26
Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML
Ascentage Pharma Group Inc.
Phase 1/2 Recruiting
NCT06423911 2025-06-03
POLARIS-2
Ascentage Pharma Group Inc.
Phase 3 Recruiting
NCT04126681 2025-03-03
A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase
Ascentage Pharma Group Inc.
Phase 2 Completed
NCT06640361 2024-12-27
A Study of Olverembatinib in SDH-deficient GIST.
Ascentage Pharma Group Inc.
Phase 3 Recruiting
NCT03883087 2023-04-03
A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Chronic Phase With T315I Mutation
Ascentage Pharma Group Inc.
Phase 2 Unknown
NCT03883100 2023-04-03
A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Accelerated Phase With T315I Mutation
Ascentage Pharma Group Inc.
Phase 2 Unknown
NCT04126707 2021-09-08
The Absorption, Metabolism and Excretion of [14C] HQP1351 in Humans
Ascentage Pharma Group Inc.
Phase 1 Completed
NCT03882281 2020-01-22
CML
Ascentage Pharma Group Inc.
Phase 1 Completed